ONC-201

DRUG2 trials

Sponsors

Fox Chase Cancer Center, University of Nebraska

Conditions

Acute Myeloid LeukemiaAdvanced Solid TumorsMultiple MyelomaMyelodysplastic Syndromes

Phase 1

A Dose-Escalation Study of Onc201 Administered Every One or Three Weeks in Advanced Solid Tumors and Multiple Myeloma

CompletedNCT02609230

Fox Chase Cancer CenterAdvanced Solid Tumors, Multiple Myeloma

Start: 2015-11-05End: 2020-03-26Updated: 2021-06-04

ONC-201 Maintenance Therapy in Acute Myeloid Leukemia and Myelodysplastic Syndrome After Stem Cell Transplant

CompletedNCT03932643

University of NebraskaAcute Myeloid Leukemia, Myelodysplastic Syndromes

Start: 2019-07-30End: 2025-03-27Updated: 2026-05-28

Related Papers

Dordaviprone Maintenance After Allogeneic HCT for High-Risk Acute Myeloid Leukemia and Myelodysplastic Neoplasm.

2026-06-26

Phase I trial of a novel first-in-class drug ONC201 as a post-transplant maintenance for acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS)

Blood2025-11-03

Novel First-in-Class Drug ONC201 As a Post-Transplant Maintenance for AML and MDS: A Phase I Trial in Progress

Blood2022-11-152 citations

Single Agent and Synergistic Combinatorial Efficacy of First-in-Class Small Molecule Imipridone ONC201 in Hematological Malignancies In Vitro and In Vivo through Apoptosis Via the Integrated Stress Response Pathway

Blood2017-12-07

A dose-escalation study of imipridone ONC201 administered every one (QW) or three weeks (Q3W) in advanced solid tumors and multiple myeloma.

Journal of Clinical Oncology2017-05-20

Abstract 3000: Intra-tumoral accumulation of NK1.1/CD3+ cells and anti-metastasis effects of dose-intensified ONC201 in tumor-bearing mice

Cancer Research2016-07-152 citations

Abstract 3012: ONC201 induces cell death in triple negative, BRCA1-deficient and non-triple negative breast cancer cells

Cancer Research2016-07-15

Abstract 3309: Novel small molecule ONC201 induces cell death and targets chemotherapy-resistant cancer stem-like cells in triple negative breast cancer

Cancer Research2016-07-15

Abstract 3087: Combination of ONC201 and bevacizumab significantly impacts colorectal cancer growth and metastasis <i>in vivo</i>

Cancer Research2016-07-15

Abstract 349: Structure-activity relationships and mechanistic analysis of analogues of the clinical-stage anti-cancer small molecule ONC201

Cancer Research2016-07-15